Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.

[1]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[2]  B. Gersh,et al.  Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. , 2009, The New England journal of medicine.

[3]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[4]  J. Hulot,et al.  The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non‐ST acute coronary syndrome , 2009, Journal of thrombosis and haemostasis : JTH.

[5]  Renu Virmani,et al.  One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. , 2009, JACC. Cardiovascular imaging.

[6]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[7]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[8]  P. Morange,et al.  A037 Impact of the CYP2C19*17 allele on platelet response to clopidogrel in patients suffering from non–st elevation acute coronary syndrome , 2009 .

[9]  A. Kastrati,et al.  Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. , 2008, European heart journal.

[10]  S. Normand,et al.  Drug-eluting or bare-metal stents for acute myocardial infarction. , 2008, The New England journal of medicine.

[11]  Christopher E. Buller,et al.  2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Journal of the American College of Cardiology.

[12]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[13]  M. O’Donoghue,et al.  Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? , 2006, Circulation.

[14]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[15]  R. Califf,et al.  Impact of enoxaparin on thrombus formation, coronary blood flow, and myocardial perfusion after early invasive treatment during acute coronary syndrome: Results from the SYNERGY library , 2006 .

[16]  Young-Hak Kim,et al.  Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. , 2006, European heart journal.

[17]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[18]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[19]  P. Teirstein,et al.  Contribution of Stent Underexpansion to Recurrence After Sirolimus-Eluting Stent Implantation for In-Stent Restenosis , 2004, Circulation.

[20]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[21]  A. Kastrati,et al.  Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. , 2000, Journal of the American College of Cardiology.

[22]  A. Kastrati,et al.  Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high load , 1997, American heart journal.

[23]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[24]  P. Morange,et al.  A 037 IMPACT OF THE CYP 2 C 19 * 17 ALLELE ON PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS SUFFERING FROM NON — ST ELEVATION ACUTE CORONARY SYNDROME , 2009 .

[25]  Timi Study,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation , 2005 .

[26]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .